Bioerodible drug delivery devices
This invention relates to a bioerodible drug delivery device that can be implanted in a patient at or near an area in need of treatment. The bioerodible drug delivery device can be used to deliver a wide variety of different pharmaceutically active agents, and can do so at a controlled rate and over an extended period of time. The bioerodible drug delivery device includes a bioerodible polymeric outer housing with one or more delivery ports for delivering the pharmaceutically active agent(s) contained therein. The polymer used as the bioerodible polymeric outer housing is not substantially degraded during the dosing of the pharmaceutically active agent(s) in the bioerodible drug delivery device. The invention also provides methods of making the bioerodible drug delivery device and using it for the treatment of diseases and disorders.
1. An implantable bioerodible drug delivery device consisting of
a bioerodible drug core consisting of a pharmaceutically active agent and polyvinyl alcohol,
a bioerodible outer member that substantially surrounds the drug core, wherein the bioerodible outer member consists of poly(lactic-co-glycolic) acid (PLGA) having a lactic acid/glycolic acid present in a molar ratio ranging from and including 82:18 to 85:15; and
at least one delivery port that is permeable to the pharmaceutically active agent;
wherein the device is configured to be injected into the vitreous of an eye; and
wherein the device is configured to provide a substantially constant dosing rate of the pharmaceutically active agent for at least one month.
2. The implantable bioerodible drug delivery device according to claim 1 , wherein the pharmaceutically active agent is selected from the group consisting of anesthetics, anti-cancer agents, anti-fungal agents, anti-viral agents, cell transport/mobility impeding agents, anti-glaucoma agents, immunological response modifiers, peptides, proteins, steroidal compounds, corticosteroids, antibacterial agents, neuro-protectants, anti-inflammatory agents, anti-allergenic agents, anti-cholinesterases, miotics, and mydriatics.
3. The implantable bioerodible drug delivery device according to claim 1 , wherein the bioerodible outer member is tubular.
4. The implantable bioerodible drug delivery device according to claim 3 , wherein each end of the tubular bioerodible outer member has a delivery port.
5. The implantable bioerodible drug delivery device according to claim 1 , wherein the device is configured to provide a substantially constant dosing rate of the pharmaceutically active agent for one month to six months.
6. The implantable bioerodible drug delivery device according to claim 1 , wherein the device is configured to provide a substantially constant dosing rate of the pharmaceutically active agent for six months to one year.
7. The implantable bioerodible drug delivery device according to claim 1 , wherein the device is configured to provide a substantially constant dosing rate of the pharmaceutically active agent for one year to three years.
8. The implantable bioerodible drug delivery device according to claim 3 , wherein the pharmaceutically active agent is a corticosteroid.
9. The implantable bioerodible drug delivery device according to claim 1 , wherein the device is configured to provide a substantially constant dosing for at least two months.
10. The implantable bioerodible drug delivery device according to claim 1 , wherein the device is designed to fit through a needle with a gauge of 25 or larger.
11. The implantable bioerodible drug delivery device according to claim 4 , wherein at least one delivery port has a polymeric cap.
12. The implantable bioerodible drug delivery device according to claim 4 , wherein at least one delivery port has a polyvinyl alcohol cap.
13. The implantable bioerodible drug delivery device according to claim 1 , wherein the polyvinyl alcohol constitutes about 1 to about 20% w/w of the drug core.
14. The implantable bioerodible drug delivery device according to claim 1 , wherein the drug core was manufactured using a solution of about 5 to about 15% w/w polyvinyl alcohol.
15. The implantable bioerodible drug delivery device according to claim 1 , wherein the drug core is heat treated during manufacturing.
16. The implantable bioerodible drug delivery device according to claim 1 , wherein the device is heat treated during manufacturing.
17. An implantable bioerodible drug delivery device consisting of
a bioerodible drug core consisting of a pharmaceutically active agent and polyvinyl alcohol,
a coating consisting of polyvinyl alcohol, wherein the coating substantially surrounds the drug core,
a bioerodible outer member that substantially surrounds the drug core and the coating, wherein the bioerodible outer member consists of poly(lactic-co-glycolic) acid (PLGA) having a lactic acid/glycolic acid molar ratio ranging from and including 82:18 to 85:15; and
at least one delivery port that is permeable to the pharmaceutically active agent;
wherein the device is configured to be injected into the vitreous of an eye; and
wherein the device is configured to provide a substantially constant dosing rate of the pharmaceutically active agent for at least one month.